GeneDx is trading 4.22% up at $93.53, continuing its advance after rising 5.25% to $89.74 on September 14, 2026, with no clear company-specific catalyst identified for September 15, 2026. - Recent coverage highlights the September 9 NPC GenomeComplete collaboration with Beren Therapeutics, but does not directly attribute today’s move to it. - GeneDx is outperforming broader markets and biotechnology, leaving the immediate reason uncertain.